Maryland is currently home to 2665 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia
NCT05828108
Recruiting
Background: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Better treatments are needed. Objective: To test a new drug (bitopertin) in people with DBA. Eligibility: People aged 18 or older with DBA. Design: Participants will be screened. They will have a physical exam; they w... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA)
Register for Updates
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
NCT03206060
Recruiting
Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help. Objective: To learn the safety and tolerability of Lu-177-DOTATATE. Also, to see if it improves the length of time it takes for the cancer to return. Eligibility: Adults who have an inoperable tum... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Neuroendocrine Neoplasms
Register for Updates
Genetic and Physical Study of Childhood Nerve and Muscle Disorders
NCT01568658
Recruiting
Background: - Some nerve and muscle disorders that start early in life (before age 25), like some forms of muscular dystrophy, can run in families. However, the genetic causes of these disorders are not known. Also, doctors do not fully understand how symptoms of these disorders change over time. Researchers want to learn more about genetic nerve and muscle disorders that start in childhood by studying affected people and their family members, as well as healthy volunteers. Objectives: - To b... Read More
Gender:
ALL
Ages:
Between 1 day and 100 years
Trial Updated:
05/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Register for Updates
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
NCT06680479
Recruiting
A5422 is a phase 1, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and immunogenicity of a vaccination with stabilized CH505 TF chTrimer admixed with 3M-052-AF + Aluminum hydroxide (Alum), to assess the effect of CH505 TF chTrimer vaccine as a therapeutic vaccine in adults living with HIV-1 on suppressive antiretroviral therapy (ART) with the aim of inducing new HIV-1 Envelope (Env) B-cell neutralizing immune responses. Participants will be on stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Johns Hopkins University CRS, Baltimore, Maryland
Conditions: HIV-1
Register for Updates
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
NCT06564623
Recruiting
The purpose of this study is to evaluate the safety and the immune response of personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax) in combination with durvalumab and tremelimumab following front-line treatment in patients with advanced stage BTC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: SKCCC Johns Hopkins Medical Institution, Baltimore, Maryland
Conditions: Biliary Tract Cancers
Register for Updates
Night Owl Metabolism
NCT06507722
Recruiting
The proposed study uses a novel and rigorous randomized cross-over study design in youth (17-23y) with late and non-late chronotype (n=35 per group) to assess the glycemic effect of "aligning" an oral glucose tolerance test (OGTT) or first-meal of day to a subject's chronotype. Both groups will undergo 2 OGTTs (aligned and mis-aligned with chronotype) to compare glucose tolerance and insulin sensitivity within-subject (primary outcome) and between groups (Aim 1). Then, youth will also undergo tw... Read More
Gender:
ALL
Ages:
Between 18 years and 23 years
Trial Updated:
05/29/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: PreDiabetes, Overweight, Impaired Glucose Tolerance
Register for Updates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/29/2025
Locations: The Retina Care Center (01-023), Baltimore, Maryland
Conditions: Geographic Atrophy
Register for Updates
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Plasma Cell Myeloma
Register for Updates
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
NCT02203903
Recruiting
This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients with high risk AML and MDS.
Gender:
ALL
Ages:
Between 6 months and 80 years
Trial Updated:
05/29/2025
Locations: Tania Jain, MD, Baltimore, Maryland
Conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Register for Updates
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
NCT07008664
Recruiting
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Maryland Baltimore Washington Medical Center, Glen Burnie, Maryland
Conditions: Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Columbia, Maryland
Conditions: Neoplasms, Head and Neck
Register for Updates
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377
Recruiting
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/28/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Sickle Cell Trait
Register for Updates